These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 14962724)

  • 1. Phase IB and pharmacological study of the novel taxane BMS-184476 in combination with doxorubicin.
    Sessa C; Perotti A; Salvatorelli E; Minotti G; Viganò L; Lladò A; Capri G; Locatelli A; Colombini S; Peccatori F; Voi M; Marsoni S; Gianni L
    Eur J Cancer; 2004 Mar; 40(4):563-70. PubMed ID: 14962724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I and pharmacokinetic study of the new taxane analog BMS-184476 given weekly in patients with advanced malignancies.
    Plummer R; Ghielmini M; Calvert P; Voi M; Renard J; Gallant G; Gupta E; Calvert H; Sessa C
    Clin Cancer Res; 2002 Sep; 8(9):2788-97. PubMed ID: 12231518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I trial of weekly paclitaxel and BMS-214662 in patients with advanced solid tumors.
    Bailey HH; Alberti DB; Thomas JP; Mulkerin DL; Binger KA; Gottardis MM; Martell RE; Wilding G
    Clin Cancer Res; 2007 Jun; 13(12):3623-9. PubMed ID: 17510207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I and pharmacokinetic study of docetaxel combined with Doxil (pegylated liposomal doxorubicin) without and with granulocyte colony stimulating factor.
    Pavlick AC; Chodkiewicz C; Liebes L; Hamilton A; Wasserheit C; Hochster H; Speyer J; Phillips Z; Downey A; Sorich J; Muggia F
    Anticancer Drugs; 2004 Feb; 15(2):119-25. PubMed ID: 15075667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I and pharmacokinetic study of BMS-188797, a new taxane analog, administered on a weekly schedule in patients with advanced malignancies.
    Advani R; Fisher GA; Lum BL; Jambalos C; Cho CD; Cohen M; Gollerkeri A; Sikic BI
    Clin Cancer Res; 2003 Nov; 9(14):5187-94. PubMed ID: 14613998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I and pharmacokinetic trial of the novel taxane BMS-184476 administered as a 1-hour intravenous infusion in combination with cisplatin every 21 days.
    Sun W; Stevenson JP; Gallagher ML; Vaughn D; Hahn SM; Haller DG; Cohen M; Kopit J; Gallant G; O'Dwyer PJ
    Clin Cancer Res; 2003 Nov; 9(14):5221-7. PubMed ID: 14614002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Weekly paclitaxel combined with pegylated liposomal doxorubicin (CaelyxTM) given every 4 weeks: dose-finding and pharmacokinetic study in patients with advanced solid tumors.
    Briasoulis E; Pentheroudakis G; Karavasilis V; Tzamakou E; Rammou D; Pavlidis N
    Ann Oncol; 2004 Oct; 15(10):1566-73. PubMed ID: 15367419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of the taxane BMS-188797 in combination with carboplatin administered every 3 weeks in patients with solid malignancies.
    Fishman MN; Garrett CR; Simon GR; Chiappori AA; Lush RM; Dinwoodie WR; Mahany JJ; Dellaportas AM; Cantor A; Gollerki A; Cohen MB; Sullivan DM
    Clin Cancer Res; 2006 Jan; 12(2):523-8. PubMed ID: 16428495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I study of paclitaxel (taxol) and pegylated liposomal doxorubicin (caelyx) administered every 2 weeks in patients with advanced solid tumors.
    Mavroudis D; Kouroussis Ch; Kakolyris S; Agelaki S; Kalbakis K; Androulakis N; Souglakos J; Samonis G; Georgoulias V
    Oncology; 2002; 62(3):216-22. PubMed ID: 12065868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I trial of the novel taxane BMS-184476 administered in combination with carboplatin every 21 days.
    Bilenker JH; Stevenson JP; Gallagher ML; Vaughn D; Cohen MB; O'Dwyer PJ
    Br J Cancer; 2004 Jul; 91(2):213-8. PubMed ID: 15213727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I trial of the novel farnesyl protein transferase inhibitor, BMS-214662, in combination with paclitaxel and carboplatin in patients with advanced cancer.
    Dy GK; Bruzek LM; Croghan GA; Mandrekar S; Erlichman C; Peethambaram P; Pitot HC; Hanson LJ; Reid JM; Furth A; Cheng S; Martell RE; Kaufmann SH; Adjei AA
    Clin Cancer Res; 2005 Mar; 11(5):1877-83. PubMed ID: 15756013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I and pharmacokinetic study of BMS-184476, a taxane with greater potency and solubility than paclitaxel.
    Hidalgo M; Aylesworth C; Hammond LA; Britten CD; Weiss G; Stephenson J; Schwartz G; Patnaik A; Smith L; Molpus K; Felton S; Gupta E; Ferrante KJ; Tortora A; Sonnichsen DS; Skillings J; Rowinsky EK
    J Clin Oncol; 2001 May; 19(9):2493-503. PubMed ID: 11331328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I dose-escalation study of cabazitaxel administered in combination with cisplatin in patients with advanced solid tumors.
    Lockhart AC; Sundaram S; Sarantopoulos J; Mita MM; Wang-Gillam A; Moseley JL; Barber SL; Lane AR; Wack C; Kassalow L; Dedieu JF; Mita AC
    Invest New Drugs; 2014 Dec; 32(6):1236-45. PubMed ID: 25117475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer.
    Amadori D; Frassineti GL; Zoli W; Milandri C; Tienghi A; Ravaioli A; Gentile A; Salzano E
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):16-22. PubMed ID: 8893894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I and pharmacokinetic study of novel taxane BMS-188797 and cisplatin in patients with advanced solid tumours.
    du Bois A; Jung B; Loehr A; Schaller-Kranz T; Cohen M; Frickhofen N
    Br J Cancer; 2006 Jan; 94(1):79-84. PubMed ID: 16333310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I trial to determine the safety, pharmacokinetics, and pharmacodynamics of intercalated BMS-690514 with paclitaxel/carboplatin (PC) in advanced or metastatic solid malignancies.
    Chow LQ; Jonker DI; Dy GK; Nicholas G; Fortin C; Patricia D; Adjei AA; Belani CP; Gupta A; Park JS; Zhang S; Sbar EI; Laurie SA
    Cancer Chemother Pharmacol; 2013 May; 71(5):1273-85. PubMed ID: 23468081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
    Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
    Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I study of Triapine in combination with doxorubicin in patients with advanced solid tumors.
    Schelman WR; Morgan-Meadows S; Marnocha R; Lee F; Eickhoff J; Huang W; Pomplun M; Jiang Z; Alberti D; Kolesar JM; Ivy P; Wilding G; Traynor AM
    Cancer Chemother Pharmacol; 2009 May; 63(6):1147-56. PubMed ID: 19082825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Study of dose escalation and sequence switching of administration of the combination of docetaxel and doxorubicin in advanced breast cancer.
    Itoh K; Sasaki Y; Fujii H; Minami H; Ohtsu T; Wakita H; Igarashi T; Watanabe Y; Onozawa Y; Kashimura M; Ohashi Y
    Clin Cancer Res; 2000 Oct; 6(10):4082-90. PubMed ID: 11051260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I and pharmacokinetic study of sequential paclitaxel and trabectedin every 2 weeks in patients with advanced solid tumors.
    Chu Q; Mita A; Forouzesh B; Tolcher AW; Schwartz G; Nieto A; Soto-Matos A; Alfaro V; Lebedinsky C; Rowinsky EK
    Clin Cancer Res; 2010 May; 16(9):2656-65. PubMed ID: 20406837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.